IPO Boutique

Galmed Pharmaceuticals Ltd. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Galmed Pharmaceuticals Ltd., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Galmed Pharmaceuticals Ltd.GLMD -
NASDAQ
Priced at $13.50 $0.00 $0.002.84 million3/13/2014
Maxim Group LLC
Co-Manager(s):
MLV & Co., Feltl & Co.
Filing(s):

Filed 2014-02-06



About Galmed Pharmaceuticals Ltd. (adapted from Galmed Pharmaceuticals Ltd. prospectus):
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing our proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs.

This description is adapted from Galmed prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as Galmed "GLMD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved